![Factory making N-Methyl-N-((3r,4r)-4-Methylpiperidin-3-Yl)-7h-Pyrrolo[2,3-D]Pyrimidin-4-Amine - Semaglutide for Type 2 Diabetes – Gentolex Featured Image](https://cdn.globalso.com/gentolexgroup/Semaglutide-for-Anti-diabetics.jpg)
Factory making N-Methyl-N-((3r,4r)-4-Methylpiperidin-3-Yl)-7h-Pyrrolo[2,3-D]Pyrimidin-4-Amine - Semaglutide for Type 2 Diabetes – Gentolex
Factory making N-Methyl-N-((3r,4r)-4-Methylpiperidin-3-Yl)-7h-Pyrrolo[2,3-D]Pyrimidin-4-Amine - Semaglutide for Type 2 Diabetes – Gentolex Detail:
Product Detail
| Name | Semaglutide |
| CAS number | 910463-68-2 |
| Molecular formula | C187H291N45O59 |
| Molecular weight | 4113.57754 |
| EINECS Number | 203-405-2 |
Synonyms
Sermaglutide; Semaglutide fandachem; Semaglutide impurity; Sermaglutide USP/EP; semaglutide; Sermaglutide CAS 910463 68 2; Ozempic,
Description
Semaglutide is a new generation of GLP-1 (glucagon-like peptide-1) analogs, and semaglutide is a long-acting dosage form developed based on the basic structure of liraglutide, which has a better effect in the treatment of type 2 diabetes. Novo Nordisk has completed 6 Phase IIIa studies of semaglutide injection, and submitted a new drug registration application for semaglutide weekly injection to the U.S. Food and Drug Administration (FDA) on December 5, 2016. A Marketing Authorization Application (MAA) was also submitted to the European Medicines Agency (EMA).
Compared with liraglutide, semaglutide has a longer aliphatic chain and increased hydrophobicity, but semaglutide is modified with a short chain of PEG, and its hydrophilicity is greatly enhanced. After PEG modification, it can not only bind closely to albumin, cover the enzymatic hydrolysis site of DPP-4, but also reduce renal excretion, prolong the biological half-life, and achieve the effect of long circulation.
Application
Semaglutide is a long-acting dosage form developed based on the basic structure of liraglutide, which is more effective in treating type 2 diabetes.
Bioactivity
Semaglutide (Rybelsus, Ozempic, NN9535, OG217SC, NNC0113-0217) is a long-acting glucagon-like peptide 1 (GLP-1) analog, an agonist of GLP-1receptor, with a potential type 2 Therapeutic efficacy of diabetes mellitus (T2DM).
Quality System
In general, quality system and assurance is in place covering all stage of production of the finished product. Adequate manufacturing and control operations are performed in compliance with the approved procedures/ specifications. Change control and Deviation handling system is in place, and necessary impact assessment and investigation were conducted. Proper procedures are in place to ensure quality of product prior to release into the market.
Product detail pictures:
![Factory making N-Methyl-N-((3r,4r)-4-Methylpiperidin-3-Yl)-7h-Pyrrolo[2,3-D]Pyrimidin-4-Amine - Semaglutide for Type 2 Diabetes – Gentolex detail pictures](https://cdn.globalso.com/gentolexgroup/Semaglutide.jpg)
Related Product Guide:
Our business puts emphasis on the administration, the introduction of talented personnel, as well as the construction of team building, trying hard to further improve the standard and liability consciousness of staff members customers. Our enterprise successfully attained IS9001 Certification and European CE Certification of Factory making N-Methyl-N-((3r,4r)-4-Methylpiperidin-3-Yl)-7h-Pyrrolo[2,3-D]Pyrimidin-4-Amine - Semaglutide for Type 2 Diabetes – Gentolex , The product will supply to all over the world, such as: Gambia, Cyprus, New Zealand, At Present, our products have been exported to more than sixty countries and different regions, such as Southeast Asia, America, Africa, Eastern Europe, Russia, Canada etc. We sincerely hope to establish wide contact with all potential customers both in China and the rest part of the world.
By Ricardo from Florida - 2017.12.19 11:10
High production efficiency and good product quality, fast delivery and completed after-sale protection, a right choice, a best choice.
By Christine from Estonia - 2018.06.21 17:11
